Analysts Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) PT at $16.60

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $16.60.

Several analysts recently weighed in on VIGL shares. Guggenheim reduced their price objective on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a report on Friday, November 8th. Wedbush lifted their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, William Blair initiated coverage on shares of Vigil Neuroscience in a research note on Wednesday. They issued an “outperform” rating on the stock.

Institutional Trading of Vigil Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC bought a new stake in shares of Vigil Neuroscience in the 2nd quarter worth $26,000. Renaissance Technologies LLC grew its holdings in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vigil Neuroscience in the second quarter worth $87,000. Geode Capital Management LLC lifted its position in shares of Vigil Neuroscience by 41.9% during the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the last quarter. Finally, Walleye Capital LLC grew its stake in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares during the period. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Trading Up 0.9 %

Shares of VIGL opened at $2.33 on Wednesday. The firm’s 50 day moving average is $3.31 and its 200-day moving average is $3.59. The stock has a market capitalization of $95.25 million, a PE ratio of -1.13 and a beta of 1.65. Vigil Neuroscience has a 12 month low of $2.08 and a 12 month high of $6.06.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.